Abstract
Background Routine childhood vaccination improves health and prevents morbidity and mortality from vaccination preventable diseases. There are indications that the COVID-19 pandemic has negatively impacted vaccination rates globally, but systematic studies on this are still lacking in Canada. This study aims to add knowledge on the effect of the pandemic on pneumococcal vaccination rates of children using self-reported immunization data entered into the CANImmunize digital vaccination tool.
Methodology An interrupted time series analysis was conducted on aggregated monthly enrollment of children on the platform (2016-2021) and their pneumococcal immunization series completion rates (2016-2020). Predicted trends before and after the onset of the COVID-19 related restriction (March 1, 2020) were compared by means of an Autoregressive Integrated Moving Average (ARIMA).
Results Pandemic restrictions were associated with changes in self-reported pneumococcal immunization rates amongst the users of the CANImmunize platform. The monthly enrollment of children on the platform decreased by – 1177.52 records (95% CI: –1865.47, – 489.57), with a continued decrease of 80.84 records each month. Self-reported pneumococcal immunization series completion rates had an immediate increase of 14.57% (95% CI 4.64, 24.51) followed by a decrease of –3.54% each month.
Conclusion The onset of the COVID-19 related restrictions impacted enrollment of children in the CANImmunize digital immunization platform, and an overall decrease in self-reported pneumococcal immunization series completion rates. Our findings support that efforts to increase catch-up immunization campaigns so that children who could not get scheduled immunization during the pandemic are not missed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee/IRB of the Ottawa Health Science Network Research Ethics Board (OHSN-REB) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at: Ntacyabukura, Blaise (2022), Children enrolment on CANImmunize and the pneumococcal vaccine's completion rate dataset, Mendeley Data, V1, DOI: 10.17632/bxspw2d2wx.1
